10 completed, 2 terminated, 1 active not recruiting. 13 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 10, Terminated 2, Active not recruiting 1 |
| Phase 2 | 7 | Completed 5, Terminated 2 |
Follow Food Allergy: new trials by email Literature Review of Food Allergy trials Research Report on Food Allergy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PK/PD Study of IN-001 Sublingual Spray in Healthy Adults Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray - Food Allergy, Anaphylaxis | Phase 1 | Completed | Insignis Therapeutics, Inc. | 32 | 2025-10-24 | 2026-05-05 |
| Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy linvoseltamab, dupilumab - Food Allergy | Phase 1 | Active not recruiting | Regeneron Pharmaceuticals | 6 | 2024-05-17 | 2026-06-26 |
| JAK Inhibition in Food Allergy Abrocitinib - Food Allergy | Phase 1 | Completed | Icahn School of Medicine at Mount Sinai | 71 | 2022-05-16 | 2025-07-04 |
| Open-label Extension Study of ADP101 ADP101 - Food Allergy | Phase 1 / Phase 2 | Terminated | Alladapt Immunotherapeutics, Inc. | 45 | 2022-03-14 | 2024-03-26 |
| ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults Low dose ADP101, High dose ADP101, Pooled Placebo - Food Allergy | Phase 1 / Phase 2 | Completed | Alladapt Immunotherapeutics, Inc. | 73 | 2021-04-20 | 2024-05-16 |
| Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy Peanut Immunotherapy - Food Allergy, Peanut Allergy | Phase 1 / Phase 2 | Terminated | University Hospital, Geneva | 12 | 2019-04-01 | 2023-08-28 |
| A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients Glucopyranosyl Lipid A (GLA), Sublingual Immuno Therapy (SLIT) Peanut Extract (PE), Placebo for GLA - Food Allergy | Phase 1 | Completed | Sanofi | 27 | 2018-05-07 | 2022-04-25 |
| Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients Xolair, Placebo - Food Allergy | Phase 1 / Phase 2 | Completed | Stanford University | 48 | 2015-03-18 | 2018-01-12 |
| Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy Viaskin Milk 150 mcg, Viaskin Milk 300 mcg, Viaskin Milk 500 mcg - Food Allergy | Phase 1 / Phase 2 | Completed | DBV Technologies | 198 | 2014-11-01 | 2024-11-20 |
| Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial Omalizumab, placebo - Peanut Allergy, Food Allergy | Phase 1 / Phase 2 | Completed | Boston Children's Hospital | 36 | 2013-01-01 | 2023-02-21 |
| Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Liquid peanut extract (Peanut SLIT) - Peanut Hypersensitivity, Food Hypersensitivity | Phase 1 / Phase 2 | Completed | University of North Carolina, Chapel Hill | 54 | 2011-06-01 | 2019-06-12 |
| Atopy Patch Test in Children With Food Allergy-related Gastrointestinal Symptoms Atopy patch test with food allergen - Food Allergy | Phase 1 | Completed | Mahidol University | 40 | 2010-04-01 | 2015-09-18 |
| Trichuris Suis Ova in Peanut and Tree Nut Allergy Trichuris suis ova (TSO) - Food Allergy | Phase 1 | Completed | Beth Israel Deaconess Medical Center | 18 | 2010-02-01 | 2017-02-03 |
Food Hypersensitivity (13) · Peanut Hypersensitivity (7) · Hypersensitivity (3) · Milk Hypersensitivity (3) · Nut Hypersensitivity (3) · Egg Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Immune System Diseases (2) · Shellfish Hypersensitivity (2) · Wheat Hypersensitivity (2) · Anaphylaxis (1) · SeSAME syndrome (1)
Hypersensitivity, Immediate (11) · Immune System Diseases (11) · Hypersensitivity (10) · Nut and Peanut Hypersensitivity (7)
Omalizumab (2) · Epinephrine (1) · Needles (1) · abrocitinib (1) · dupilumab (1) · gamma-carboxyglutamyl-gamma-carboxyglutamic acid (1) · glucopyranosyl lipid-A (1)
Alladapt Immunotherapeutics, Inc. (2) · Beth Israel Deaconess Medical Center (1) · Boston Children's Hospital (1) · DBV Technologies (1) · Icahn School of Medicine at Mount Sinai (1) · Insignis Therapeutics, Inc. (1) · Mahidol University (1) · Regeneron Pharmaceuticals (1) · Sanofi (1) · Stanford University (1) · University Hospital, Geneva (1) · University of North Carolina, Chapel Hill (1)
United States (11) · Canada (1) · Switzerland (1) · Thailand (1)
Mei-Lun Wang, MD (2) · Andrew MacGinnitie, MD, PhD (1) · Emma Guttman, MD, PhD (1) · Jacqueline Pongracic, MD (1) · Jean-Christoph Caubet, MD (1) · Jonathan Spergel, MD, PhD (1) · Kari Nadeau, MD PhD (1) · Kari Nadeau, MD, PhD (1) · Lynda C Schneider, MD (1) · Marie-Helene Jouvin, MD (1) · Nancy Sweitzer (1) · Nualanong Visitsunthorn, MD (1) · Scott Sicherer, MD (1)
PMID 27979025, PMID 29242014, PMID 33782956, PMID 34755130, PMID 38407859, PMID 38814736
2018 (1), R01AT004435 (1), U19AI104209 (1)